Jiangsu Hengrui Pharmaceuticals (600276.SH): Fosrolapitant Palonosetron for Injection Approved for Additional Indication
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. recently received a notice from the National Medical Products Administration approving an additional indication for Fosrolapitant Palonosetron for Injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection. The approved indication is "for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (MEC) in adult patients."
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration approving an additional indication for fosrolapitant palonosetron for injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection. The approved indication is "for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (MEC) in adult patients."
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






